Chemical Properties
| form | Liquid |
| color | Colorless to light yellow |
Onartuzumab Chemical Properties,Usage,Production
Description
Onartuzumab is a monoclonal antibody that blocks the binding of HGF to the MET receptor.Uses
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity[1].Clinical Use
Onartuzumab is ineffective in improving clinical outcomes in (i) combination with current first-line chemotherapy in advanced nonsquamous cell NSCLC , (ii) combination with erlotinib in previously treated stage IIIB or IV NSCLC patients (Phase III) , and (iii) combination with platinum-doublet chemotherapy in advanced squamous cell NSCLC (Phase II) .in vivo
Onartuzumab (30 mg/kg, IP, twice a week for 2 mouth) suppresses tumor growth[3].
| Animal Model: | Human HGF-transgenic SCID mice implanted with BxPC3 tumor cells, nude (nu/nu) mice implanted with KP4 human pancreatic xenograft tumor cells[3] |
| Dosage: | 30 mg/kg |
| Administration: | IP, twice a week for 2 mouth |
| Result: | Suppressed tumor growth, but did not affect the mean in vivo human HGF levels. |
| Animal Model: | U-87 MG tumor-bearing mice[3] |
| Dosage: | 30 mg/kg |
| Administration: | IP, once |
| Result: | Resulted in profound TGI (tumor growth inhibition) with 4/10 mice demonstrating a partial response (>50% reduction in tumor size) and 6/10 mice demonstrating a complete response (100% tumor regression). |
References
[1] Merchant M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96. DOI:10.1073/pnas.1302725110[2] Prell RA, et al. Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys. Toxicol Sci. 2018 Sep 1;165(1):186-197. DOI:10.1093/toxsci/kfy141
Onartuzumab Suppliers
Global(29)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | 32430 | 58 | ||
| tp@aladdinsci.com | 54731 | 58 | |||
| 6206333 13167063860 | anhua.mao@aladdin-e.com | 49544 | 58 | ||
| 17316404525 17316404525 | 209533805@qq.com | 9790 | 58 | ||
| 027-65279366 18108604356 | products@biolabreagent.com | 9864 | 58 | ||
| 021-65675885 18964387627 | customer_service@efebio.com | 11963 | 58 | ||
| 027-65317797 15926423062 | 422450190@qq.com | 10300 | 58 | ||
| 177-54423994 17754423994 | 2853530910@QQ.com | 7999 | 62 | ||
| 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | 7353 | 58 | ||
| 15111215862 18229892877 | 3062105966@qq.com | 5580 | 58 |